Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02210117 · ClinicalTrials.gov registry record · Early Phase 1

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

A Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Early Phase 1
Development phase
104
Enrollment target
1
Study location

NCT02210117 is a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 104 participants, below the 201-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02210117, a Early Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to as renal cell cancer, that has spread to another place in body and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, bevacizumab, and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v7 Metastatic Kidney Carcinoma

Interventions

  • PROCEDURE Biopsy
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Ipilimumab
  • BIOLOGICAL Bevacizumab
  • PROCEDURE Metastasectomy

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2014-11-25
Est. Completion 2026-11-30
Phase Early Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02210117

The ClinicalTrials.gov registry entry for NCT02210117 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (48% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biopsy is the first listed.

NCT02210117 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02210117 about?

NCT02210117 is a clinical study titled "Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery". This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to as renal cell cancer, that has spread to another place in body and can b...

What is the current status of trial NCT02210117?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 104 participants. The study started on 2014-11-25. Estimated completion is 2026-11-30.

What conditions does trial NCT02210117 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7, Metastatic Kidney Carcinoma.

What interventions are being tested in trial NCT02210117?

The interventions under investigation include: Biopsy (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Ipilimumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL), Metastasectomy (PROCEDURE).

Who is sponsoring clinical trial NCT02210117?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02210117 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer AJCC v7

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.